{
    "medicine_id": "87b84cda8f582f0fa50022c880345e9fdd6a9042",
    "platform_id": "DB13973",
    "metadata": {
        "name": "Prochymal Solution",
        "composition": "Remestemcel L",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for in the management of acute Graft versus Host Disease aGvHD in pediatric patients Acute GvHD should be refractory to treatment with systemic corticosteroid therapy and or other immunosuppressive agents Remestemcel L may be used for Grades C and D of the disease in any organ Remestemcel L may also be used in the management of Grade B aGvHD involving any visceral organ including the GI tract and the liver but excluding skin L11022",
            "contraindications": {
                "disease": "In a single dose toxicology study in rats the no observed adverse effect level NOAEL following IV administration was 40x106 MSC kg and the maximum tolerated dose MTD was 65x106 MSCs kg The NOAEL was a cumulative dose of 80x106 MSC kg when dosing twice per week in a repeat dose study in rats with no effects on host immune cell quantities or immune system functionality There was no evidence of alloantibody formation L11022 In a 6 week tumorigenicity study in mice there was no evidence of tumor formation attributed to human mesenchymal stem cells Standard genotoxicity and carcinogenicity studies as well as animal reproduction and developmental toxicology studies were not conducted with remestmecel L as they were not relevant for the aGvHD patient population L11022",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Remestemcel L exerts an immunomodulatory effects both in vivo and vitro by suppressing the proliferative activity of allogenic T lymphocytes In vitro there was evidence of tissue protection and tissue repair effects through reduction of pro inflammatory cytokines and secretion of factors There were no signs of electrocardiogram disturbances changes in hemoglobin saturation heart rate or respiration rate with intravenous administration of remestemcel L L11022",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}